Inventiva S.A. - רווח נקי למניה (EPS TTM) IVA

Inventiva S.A. relies on clinical drug development cycles that remain independent of macroeconomic trends. The 12-month EPS change on the GURU.Markets terminal chart reflects the current metric -1.36. The company's prospects are based on a unique steatohepatitis therapy that provides access to a massive market. However, geopolitical risks may complicate patent protection and the import of raw materials.

To minimize investment risks, Inventiva S.A. must evaluate the efficiency of profit generation relative to capital. This metric is calculated as the ratio of total annual net income to the number of shares, and analyzing the annual net income per share chart allows for a correlation between the business's financial stability and its commitment to ESG standards and biotechnological development ethics.